Evidence map›Paper›PMID 39697398›Full record

ArticleJAACAP open2024

Evaluation of the Association Between Prenatal Cannabis Use and Risk of Developmental Delay.

Dana Watts, Catherine Lebel, Kathleen Chaput, Gerald F Giesbrecht, Kyle Dewsnap, Samantha L Baglot, Lianne Tomfohr-Madsen

Abstract read
In one paragraph

Article in JAACAP open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Dana WattsUniversity of Calgary, Calgary, Alberta, Canada.
Catherine LebelUniversity of Calgary, Calgary, Alberta, Canada.
Kathleen ChaputUniversity of Calgary, Calgary, Alberta, Canada.
Gerald F GiesbrechtUniversity of Calgary, Calgary, Alberta, Canada.
Kyle DewsnapUniversity of British Columbia, Vancouver, British Columbia, Canada.
Samantha L BaglotUniversity of Calgary, Calgary, Alberta, Canada.
Lianne Tomfohr-MadsenUniversity of British Columbia, Vancouver, British Columbia, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Conflicting results have arisen regarding the association between prenatal cannabis exposure and risk of parent-reported developmental delay in infancy. In certain instances, this literature has become outdated or failed to adjust for confounding variables. The current study aimed to determine if prenatal cannabis exposure was associated with a greater likelihood of risk of parent-reported developmental delay at 12 months of age in a contemporary cohort, while adjusting for common confounding variables. Method: Participants (n = 10,695) were part of the Pregnancy During the COVID-19 Pandemic (PdP) study. A subset of the sample (n = 3,742) provided a parent-report developmental assessment, the Ages and Stages Questionnaire, Third Edition (ASQ-3), of their infant at 12 months old. Sociodemographic differences between participants who reported cannabis use (CU+ group) and those who did not (CU- group) were analyzed. To address potential heterogeneity between CU+ and CU- groups, propensity score weighting was used. G-computations were performed to analyze the association between outcome variables (gestational age, birth weight, and risk of parent-reported developmental delay) and prenatal cannabis exposure. Weighted linear or quasi-binominal logistic regression models were used, with differences of averages and odds ratios reported. Results: Participants in CU+ and CU- groups significantly differed on all sociodemographic variables. Prenatal cannabis exposure was not associated with any birth outcomes ( Conclusion: Prenatal cannabis exposure was associated with increased odds of delay on the communication domain before adjusting for multiple comparisons. No other domains were significantly associated with increased odds of delay. These findings should not be interpreted as suggesting that consuming cannabis products during pregnancy is safe for infant development. Further, the analysis was performed using data from a longitudinal sample that was not specifically created to address this question, but was leveraged to explore these outcomes. Additional studies that are specifically designed to examine these outcomes are needed. Diversity & Inclusion Statement: We worked to ensure that the study questionnaires were prepared in an inclusive way. We worked to ensure race, ethnic, and/or other types of diversity in the recruitment of human participants. The author list of this paper includes contributors from the location and/or community where the research was conducted who participated in the data collection, design, analysis, and/or interpretation of the work. One or more of the authors of this paper self-identifies as a member of one or more historically underrepresented sexual and/or gender groups in science.

Indexed as

Ages and Stages Questionnairebirth outcomescannabisinfant developmentpregnancy

Identifiers

PMID39697398
PMCPMC11650681

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.